Miso, estimated salt intake and obesity in type 2 diabetes
What it found
In 300 people with type 2 diabetes, those with high estimated salt intake who ate miso regularly were less likely to be obese than those with high estimated salt intake who did not eat miso.
This was a cross-sectional study, so it cannot show cause and effect.
What they found
Studies in people
Obesity and salt intake
People with high estimated salt intake were more likely to be obese than those with lower intake. The authors adjusted for factors like age, sex, and diabetes duration.
Miso and obesity
Among those with high estimated salt intake, those who ate miso regularly had a lower obesity rate than those who did not. The obesity rate was 40.2% with miso and 77.8% without.
Other findings
Miso and salt excretion
The authors say miso may help the body excrete salt, so urine tests might show a higher salt intake than a person actually eats.
What the authors conclude
“Clinicians should be aware that estimated salt intake may be higher than actual salt intake in people with habitual miso consumption because miso consumption promotes salt excretion.”
Also in their conclusions
- They report that obesity in people with high estimated salt intake and habitual miso consumption was lower than for people with high salt intake without miso.
- They advise that clinicians should be aware that estimated salt intake may be higher than actual salt intake in people who habitually consume miso because miso consumption promotes salt excretion.
How it was done
The authors wanted to see whether a high estimated salt intake is really linked to obesity in people who eat miso regularly, because miso may increase salt excretion and make salt intake look higher than it is.
They studied 300 people with type 2 diabetes from two hospitals in Japan. They estimated salt intake from urine, asked about miso soup consumption, and measured body fat to define obesity.
What it can’t tell you
- This was a cross-sectional study, so it cannot show whether miso or salt intake causes changes in obesity.
- The study relied on self-reported miso consumption and a formula to estimate salt intake, which may not be perfectly accurate for individuals.
- The number of people who did not eat miso was small, so the results need confirmation in larger studies.
Who paid
- Conflicts
- Hashimoto received personal fees from Sanofi K.K., Ono Phama Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corp., and Kowa Pharma Co., Ltd. outside the submitted work. Senmaru received personal fees from Takeda Pharma Co., Ltd., Astellas Pharma Inc., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Co., MSD K.K., Taisho Toyama Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Sanofi K.K., Ono Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Kowa Pharma Co., Ltd., and Kissei Pharma Co., Ltd. outside the submitted work. Ushigome received grants from the Japanese Study Group for Physiology and Management of Blood Pressure, and the Astellas Foundation for Research on Metabolic Disorders. Donated Fund Laboratory of Diabetes therapeutics is a grant from Ono Pharmaceutical Co., Ltd. In addition, she received personal fees from Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corp., AstraZeneca plc, Kowa Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Daiichi Sankyo Co., Ltd., Kyowa Hakko Kirin Company Ltd., MSD K.K., and Taisho Toyama Pharmaceutical Co., Ltd. outside the submitted work. Hamaguchi received grants from Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Asahi Kasei Pharma, Sanofi K.K., Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Eli Lilly Japan K.K., and Mitsubishi Tanabe Pharma Corporation outside the submitted work. Asano received personal fees from Ono Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, and Abbott Japan Co., Ltd. outside the submitted work. Yamazaki reports personal fees from Takeda Pharmaceutical Company Ltd., AstraZeneca PLC, Kyowa Hakko Kirin Co., Ltd., Ono Pharma Co., Ltd., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Kowa Company, Limited, Daiichi Sankyo Co., Ltd., and Kowa Pharmaceutical Co. Ltd. outside the submitted work. Prof. Fukui received grants from Sanofi K.K., Ono Pharma Co., Ltd., Novo Nordisk Pharma Ltd., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Kissei Pharma Co., Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co, Kowa Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharma Co., Ltd., Astellas Pharma Inc., Nippon Chemiphar Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Taisho Pharma Co., Ltd., Abbott Japan Co., Ltd., Terumo Co., Teijin Pharma Ltd., and Johnson & Johnson K.K. Medical Co., and received personal fees from Kissei Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corp., Novo Nordisk Pharma Ltd., Kyowa Kirin Co., Ltd., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharma Co., Ltd., Sanofi K.K., Teijin Pharma Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly Japan K.K., Taisho Pharma Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Ono Pharma Co., Ltd., Arkley Inc., Kowa Pharma Co., Ltd., AstraZeneca K.K., Mochida Pharma Co., Ltd., Abbott Japan Co., Ltd., Medtronic Japan Co., Ltd., and Nipro Cor. outside the submitted work.
- Authors work at
- Kyoto Prefectural University of Medicine, Japan; Kameoka Municipal Hospital, Japan; Matsushita Memorial Hospital, Japan
The paper
- Title
- Association of Estimated Salt and Miso Intake with the Prevalence of Obesity in People with Type 2 Diabetes: A Cross-Sectional Study
- Type
- Study
- Evidence
- Studies in people
- Summarised from
- Full text
- Licence
- CC BY. Words in quotation marks are the authors’; the rest is our summary.
- Cite
- Takahashi F, Hashimoto Y, Kaji A, et al (2021). Association of Estimated Salt and Miso Intake with the Prevalence of Obesity in People with Type 2 Diabetes: A Cross-Sectional Study. Nutrients. doi:10.3390/nu13093014Free full textPubMed 34578892DOI
Summary written 30 Sep 2026. Check it against the paper before it changes what you eat. How we summarise papers · Report an error